

The Center for Vaccine Research

PRA Health Sciences' Center for Vaccine Research is a cross-divisional, highly experienced team dedicated to providing customized solutions and hands-on support for operationalizing vaccine and emerging infectious disease (EID) studies.

Executive Summary

We partner with you to build a development program uniquely fit for you and your vaccine or EID treatment. Our Center utilizes a personalized, boutique-operating approach combined with state-of-the-art medical informatics solutions to deliver the latest in strategic trial design and execution. We work closely with our vaccine and EID-experienced delivery teams and our well-established vendors and sites to ensure every trial is successful.

We're a data-driven team, leveraging internal and external data sources to inform our decision-making. Our internal technologies, combined with our global infrastructure and capabilities, allow us to achieve faster start-up timelines than our competitors while reducing the burden on sites and participants with innovative tools, including our Mobile Health Platform.

We also have a dedicated Site Relationship team that evaluates investigators and sites across the globe to build strong, personal relationships that are mutually beneficial.

Expertise & Experience

- The Center has participated in 160+ vaccine trials across every phase in 20+ indications over the last five years. These studies targeted 220,000+ participants at 3,400+ sites globally.
- By the end of 2020, the Center was participating in 30 Phase I-IV COVID-19 clinical studies, targeting 109,880+ patients at 1,030+ sites globally.





"2020 brought monumental changes to the clinical research industry. I believe clinical research will forever be changed by the innovative approaches born from the COVID-19 vaccine and treatment response. PRA adapted quickly in 2020, leveraging our technology to reduce the burden of participating in a clinical trial, to collect data remotely, to predict the spread and impact of the virus, and to deliver trials in a shorter period of time with quality results. We've created new operating models applying what we have learned during COVID-19 to continue to support our vaccine and emerging infectious disease clients."

LYNLEE BURTON

Head, Center for Vaccine Research

Key Features

COMPREHENSIVE EXPERIENCE

We allow our comprehensive experience to inform and direct us in our current programs. Our curated best practices and specialized team of experts ensure we provide a superior vaccine and EID treatment offering.

SMARTER DATA

We leverage our deep data assets to target the right countries and sites at the right time, and we continuously evaluate additional data assets. This ensures we design a study that is uniquely suited for your specific vaccine or treatment.

INNOVATIVE TECHNOLOGY

We work directly with our technology teams and leverage tools like our Mobile Health Platform to improve your study's execution and reduce the burden of participation for subjects and sites.

STRATEGIC RELATIONSHIPS

We build long-lasting relationships with sites, weighing their strengths, weaknesses, and capacity when designing a program. We work with them to provide input on proposed protocols and ensure we are on target during enrollment and database lock. We also have access to Key Opinion Leaders (KOLs) throughout the industry to inform our study design.

AGILE TEAMS

We work quickly and pivot rapidly. Our flat, agile team understands the importance of quick decision making and is able to adjust when challenges arise.

Commitment

Preventable diseases are just that—preventable. We believe in the power of public health initiatives and vaccines to protect people around the world. We're driven by the work we do because we understand how many lives we can protect and health outcomes we can improve from the vaccines and treatments we develop. Clinical trials have a chance to provide care opportunities in communities where healthcare is limited. We partner with investigators in underserved areas worldwide to enroll subjects and bring healthcare into these communities.

We also consider the subject's perspective and clinical trial journey in the study's design and delivery, utilizing our Mobile Health Platform to reduce the burden of participation and data collection for the subject and site. We're committed to improving the clinical development journey for all stakeholders.

Contact

Lynlee Burton, Head, Center for Vaccine Research, BurtonLynlee@prahealthsciences.com

Mark Sorrentino, Vice President, Center for Vaccine Research, SorrentinoMark@prahealthsciences.com

Darin Seehafer, Sr. Director of Therapeutic Expertise, Center for Vaccine Research, SeehaferDarin@prahealthsciences.com